INS and diabetes mellitus: The very limited available literature on the perspectives of HCPs identified that most involved in the care of patients with diabetes were willing to both initiate biosimilars in insulin naïve patients as well as switch existing patients, although concerns were understandably higher with respect to switching [32, 33, 37].